Insigneo Advisory Services LLC Has $397,000 Stock Holdings in Hologic, Inc. (NASDAQ:HOLX)

Insigneo Advisory Services LLC boosted its stake in Hologic, Inc. (NASDAQ:HOLX) by 6.1% during the first quarter, according to the company in its most recent filing with the SEC. The fund owned 6,428 shares of the medical equipment provider’s stock after buying an additional 367 shares during the period. Insigneo Advisory Services LLC’s holdings in Hologic were worth $397,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds have also bought and sold shares of HOLX. Venturi Wealth Management LLC grew its position in shares of Hologic by 156.3% in the fourth quarter. Venturi Wealth Management LLC now owns 428 shares of the medical equipment provider’s stock valued at $31,000 after purchasing an additional 261 shares during the last quarter. EverSource Wealth Advisors LLC boosted its stake in Hologic by 79.8% in the 4th quarter. EverSource Wealth Advisors LLC now owns 586 shares of the medical equipment provider’s stock valued at $42,000 after purchasing an additional 260 shares during the period. Smartleaf Asset Management LLC grew its holdings in Hologic by 36.9% in the 4th quarter. Smartleaf Asset Management LLC now owns 590 shares of the medical equipment provider’s stock valued at $43,000 after buying an additional 159 shares in the last quarter. Smithfield Trust Co increased its position in Hologic by 160.0% during the 4th quarter. Smithfield Trust Co now owns 650 shares of the medical equipment provider’s stock worth $45,000 after buying an additional 400 shares during the period. Finally, Raiffeisen Bank International AG acquired a new stake in shares of Hologic during the fourth quarter worth $49,000. Institutional investors and hedge funds own 94.73% of the company’s stock.

Insider Activity at Hologic

In related news, Director Martin D. Madaus purchased 5,445 shares of Hologic stock in a transaction on Wednesday, May 7th. The shares were purchased at an average price of $55.24 per share, for a total transaction of $300,781.80. Following the transaction, the director now owns 5,445 shares of the company’s stock, valued at approximately $300,781.80. This represents a ∞ increase in their position. The purchase was disclosed in a legal filing with the SEC, which is available at this hyperlink. 1.88% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

A number of research firms recently commented on HOLX. Raymond James Financial reaffirmed an “outperform” rating and set a $71.00 price target (down from $90.00) on shares of Hologic in a research report on Friday, May 2nd. Royal Bank Of Canada dropped their price target on shares of Hologic from $75.00 to $70.00 and set a “sector perform” rating for the company in a research report on Friday, May 2nd. Needham & Company LLC reiterated a “hold” rating on shares of Hologic in a research note on Tuesday, May 27th. Stephens lowered their price objective on Hologic from $77.00 to $70.00 and set an “overweight” rating on the stock in a research note on Tuesday, May 13th. Finally, Evercore ISI dropped their price objective on Hologic from $65.00 to $62.00 and set an “in-line” rating for the company in a report on Friday, May 2nd. Twelve research analysts have rated the stock with a hold rating, five have given a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, Hologic currently has a consensus rating of “Hold” and an average price target of $77.42.

Hologic Trading Down 0.3%

HOLX opened at $63.97 on Thursday. The company has a market cap of $14.26 billion, a P/E ratio of 26.99, a PEG ratio of 2.35 and a beta of 0.55. The company has a current ratio of 3.24, a quick ratio of 2.52 and a debt-to-equity ratio of 0.54. The company’s 50 day moving average is $59.03 and its 200-day moving average is $64.64. Hologic, Inc. has a 1-year low of $51.90 and a 1-year high of $84.67.

Hologic (NASDAQ:HOLX) last issued its earnings results on Thursday, May 1st. The medical equipment provider reported $1.03 earnings per share for the quarter, beating analysts’ consensus estimates of $1.02 by $0.01. The firm had revenue of $1.01 billion for the quarter, compared to analyst estimates of $1 billion. Hologic had a net margin of 13.83% and a return on equity of 19.71%. The company’s quarterly revenue was down 1.2% on a year-over-year basis. During the same quarter last year, the business posted $1.03 earnings per share. Equities research analysts predict that Hologic, Inc. will post 4.28 earnings per share for the current fiscal year.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.